share_log

TransMedics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

TransMedics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

transmedics將參加摩根士丹利第22屆全球醫療保健會議
PR Newswire ·  08/21 16:05

ANDOVER, Mass., Aug. 21, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference at the Marriott Marquis New York. The fireside chat will take place on Wednesday, September 4, 2024, at 1:05 p.m. Eastern Time.

麻省安多弗,2024年8月21日/美通社/ -- 醫療技術公司TransMedics Group, Inc.(「TransMedics」)(納斯達克:TMDX)正在爲患有晚期肺臟、心臟和肝臟衰竭的患者轉變器官移植治療。今天宣佈該公司管理團隊的成員將參加摩根士丹利第22屆年度全球醫療保健大會上的座談會,該會議將在紐約萬豪酒店舉行。座談會將於2024年9月4日星期三下午1:05(東部時間)舉行。

Event: Morgan Stanley 22nd Annual Global Healthcare Conference
Date: Wednesday, September 4, 2024
Time: 1:05 p.m. ET

活動:摩根士丹利第22屆年度全球醫療保健大會
日期:2024年9月4日星期三
時間:下午1:05(東部時間)

A live and archived webcast of the fireside chat will be available on the "Investors" section of the TransMedics website at . The Company's standard investor presentation is also available through this link.

座談會的音頻和存檔將在TransMedics網站的「投資者」頁面上提供。該公司的標準投資者介紹也可以通過此鏈接獲得。

About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

關於transmedics group,inc。
transmedics是世界上便攜式體外溫熱灌注和評估供體器官移植的領先者。該公司總部位於美國馬薩諸塞州安多弗,旨在解決器官移植的需求問題,開發出了保存器官質量、評估器官移植前的可能性和潛在增加供體器官利用率的技術,用於治療終末心臟、肺和肝功能衰竭。

Investor Contact:
Brian Johnston
332-895-3222
[email protected]

投資者聯繫人:
Brian Johnston
332-895-3222
[email protected]

SOURCE TransMedics Group, Inc.

資料來源:transmedics group,inc。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論